MYC及BCL-2蛋白双表达对弥漫大B细胞淋巴瘤患者预后影响：倾向性评分匹配分析

OBJECTIVE: We investigated the impact of MYC/BCL-2 protein co-expression on the prognosis of diffuse large B-cell lymphoma（DLBCL）patients and observed whether double expression（DE）remains an independent poor prognostic factor in DLBCL after the addition of therapeutic factors such as DA-EPOCH-R, central prophylaxis, and transplantation. METHODS: Available pathological findings were retrospectively collected from 223 DLBCL patients at the Peking Union Medical College Hospital from 2015 to 2018. Seventy-five patients with high MYC/BCL-2 expression were categorized as the DE group. From the 148 non-DE patients, 75 DLBCL patients were selected as the control group, using a 1∶1 matching on propensity scores for age, international prognostic index score, treatment choice, and etc. The differences in overall survival（OS）and progression-free survival（PFS）between the two groups were compared. RESULTS: The 3-year OS was（69.8±5.5）％ for the DE group and（77.0±4.9）％ for the non-DE group（P＝0.225）, while the 3-year PFS was（60.7±5.8）％ and（65.3±5.5）％, respectively（P＝0.390）. Subgroup analysis in patients treated with the R-CHOP regimen revealed that for the DE and non-DE patients, the 3-year OS was（61.3±7.5）％ and（77.2±5.6）％（P＝0.027）, and the 3-year PFS was（52.1±7.5）％ and（70.6±6.0）％（P＝0.040）, respectively. Multivariate analysis showed that age, stage of Ann Arbor, COO staging, whether central prophylaxis was performed, and whether transplantation was performed were significant independent risk factors of the prognosis of DLBCL patients（P<0.05）. On the other hand, MYC/BCL-2 protein double expression was not significantly associated with prognostic outcomes. CONCLUSION: MYC/BCL-2 protein double expression was significantly associated with poor prognosis under R-CHOP regimen treatment, but the poor prognostic impact of DE on DLBCL was eliminated under intensive regimens such as DA-EPOCH-R and transplantation.